Logo image of CALC

CALCIMEDICA INC (CALC) Stock Fundamental Analysis

NASDAQ:CALC - Nasdaq - US38942Q2021 - Common Stock - Currency: USD

1.72  -0.03 (-1.71%)

After market: 1.8 +0.08 (+4.65%)

Fundamental Rating

1

Taking everything into account, CALC scores 1 out of 10 in our fundamental rating. CALC was compared to 195 industry peers in the Pharmaceuticals industry. CALC has a bad profitability rating. Also its financial health evaluation is rather negative. CALC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CALC had negative earnings in the past year.
CALC had a negative operating cash flow in the past year.
In the past 5 years CALC always reported negative net income.
CALC had a negative operating cash flow in each of the past 5 years.
CALC Yearly Net Income VS EBIT VS OCF VS FCFCALC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -74.45%, CALC is doing worse than 68.21% of the companies in the same industry.
CALC has a worse Return On Equity (-173.33%) than 66.15% of its industry peers.
Industry RankSector Rank
ROA -74.45%
ROE -173.33%
ROIC N/A
ROA(3y)-146.96%
ROA(5y)-105.36%
ROE(3y)-205.06%
ROE(5y)-141.38%
ROIC(3y)N/A
ROIC(5y)N/A
CALC Yearly ROA, ROE, ROICCALC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

CALC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CALC Yearly Profit, Operating, Gross MarginsCALC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

CALC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CALC has more shares outstanding
CALC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CALC Yearly Shares OutstandingCALC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CALC Yearly Total Debt VS Total AssetsCALC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -10.35, we must say that CALC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CALC (-10.35) is worse than 70.77% of its industry peers.
A Debt/Equity ratio of 0.79 indicates that CALC is somewhat dependend on debt financing.
CALC has a worse Debt to Equity ratio (0.79) than 68.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z -10.35
ROIC/WACCN/A
WACCN/A
CALC Yearly LT Debt VS Equity VS FCFCALC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

CALC has a Current Ratio of 5.66. This indicates that CALC is financially healthy and has no problem in meeting its short term obligations.
CALC's Current ratio of 5.66 is fine compared to the rest of the industry. CALC outperforms 74.87% of its industry peers.
A Quick Ratio of 5.66 indicates that CALC has no problem at all paying its short term obligations.
CALC's Quick ratio of 5.66 is fine compared to the rest of the industry. CALC outperforms 75.38% of its industry peers.
Industry RankSector Rank
Current Ratio 5.66
Quick Ratio 5.66
CALC Yearly Current Assets VS Current LiabilitesCALC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

CALC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.58%, which is quite impressive.
EPS 1Y (TTM)25.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3700%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CALC will show a very negative growth in Earnings Per Share. The EPS will decrease by -15.47% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-29.16%
EPS Next 2Y-19.08%
EPS Next 3Y-15.47%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CALC Yearly Revenue VS EstimatesCALC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2M 4M 6M 8M
CALC Yearly EPS VS EstimatesCALC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CALC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CALC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CALC Price Earnings VS Forward Price EarningsCALC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CALC Per share dataCALC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

CALC's earnings are expected to decrease with -15.47% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.08%
EPS Next 3Y-15.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CALC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CALCIMEDICA INC

NASDAQ:CALC (6/13/2025, 8:00:02 PM)

After market: 1.8 +0.08 (+4.65%)

1.72

-0.03 (-1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-11 2025-08-11/amc
Inst Owners57.77%
Inst Owner Change-7.22%
Ins Owners11.21%
Ins Owner Change0.05%
Market Cap24.03M
Analysts84
Price Target16.32 (848.84%)
Short Float %1.12%
Short Ratio3.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.39%
Min EPS beat(2)-15.09%
Max EPS beat(2)-5.69%
EPS beat(4)2
Avg EPS beat(4)3.38%
Min EPS beat(4)-15.09%
Max EPS beat(4)32.99%
EPS beat(8)5
Avg EPS beat(8)26.81%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)13.18%
EPS NQ rev (3m)-109.98%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.21
P/tB 2.21
EV/EBITDA N/A
EPS(TTM)-1.6
EYN/A
EPS(NY)-1.74
Fwd EYN/A
FCF(TTM)-1.53
FCFYN/A
OCF(TTM)-1.53
OCFYN/A
SpS0
BVpS0.78
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.45%
ROE -173.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-146.96%
ROA(5y)-105.36%
ROE(3y)-205.06%
ROE(5y)-141.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.66
Quick Ratio 5.66
Altman-Z -10.35
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)79.82%
Cap/Depr(5y)117.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3700%
EPS Next Y-29.16%
EPS Next 2Y-19.08%
EPS Next 3Y-15.47%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.96%
EBIT Next 3Y-13.69%
EBIT Next 5YN/A
FCF growth 1Y3.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.89%
OCF growth 3YN/A
OCF growth 5YN/A